KMT2A and leukemia: Patients with t(4;11)(q21;q23) Mixed-Lineage Leukemia (MLL) rearrangements belong to the poor-risk cytogenetic category, with overall disease-free survival (DFS) rate of about 25%, and produce an AF4/MLL fusion gene [12].